latest-news-headlines Market Intelligence /marketintelligence/en/news-insights/latest-news-headlines/s-p-further-downgrades-mednax-s-ratings-after-anesthesia-division-sale-58572022 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

S&P further downgrades Mednax's ratings after anesthesia division sale

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

S&P further downgrades Mednax's ratings after anesthesia division sale

S&P Global Ratings further downgraded Mednax Inc.'s long-term issuer credit rating to B+ from BB-, following the company's sale of its anesthesia business.

The outlook on the rating is stable.

Earlier in May, North American Partners in Anesthesia LLP completed its acquisition of American Anesthesiology Inc., which has been facing multiple business challenges since 2017.

According to the rating agency, the incremental strengthening of the business risk from the sale is more than offset by the considerable increase in debt leverage.

Mednax's adjusted net leverage is estimated to be materially above 5x for an extended time due to severe EBITDA pressure from the COVID-19 pandemic, along with pressure from UnitedHealth Group Inc.'s terminations of all contracts with the company, elevated restructuring costs and increased overhead operating expenses.

Ratings expects leverage to return to about 6x in 2022, as COVID-19-related pressures and restructuring costs subside.

Although the sale materially cuts Mednax's size and diversification, the rating agency sees the company as fundamentally stronger than some of its staffing peers, thanks to its high concentration in the high-margin, relatively stable neonatal segment. The sale also boosts the company's margin profile and lessens reimbursement uncertainties.

Also, while Ratings expects Mednax's EBITDA to suffer materially in the second and third quarters, the rating agency expects the company to maintain sufficient liquidity to absorb significant losses.

The stable outlook reflects the agency's expectation that Mednax will continue to grow through acquisitions and finance them through internally generated cash flow and some incremental debt issuance, keeping its average leverage above 5x over time.

This S&P Global Market Intelligence news article may contain information about credit ratings issued by S&P Global Ratings, a separately managed division of S&P Global. Descriptions in this news article were not prepared by S&P Global Ratings.